Saltar al contenido
Merck

Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet (2014-05-24)
Pawana Panomket, Suthinee Thirat, Surasak Wanram, Rungnapa Pankla Sranujit
RESUMEN

Staphylococcus aureus is a species of bacteria that causes a number of diseases and more than 60% of it is presently resistant to methicillin. Vancomycin is the drug of choice for the eradication of methicillin-resistant S. aureus (MRSA). This study aimed to investigate the susceptibility of heterogeneous vancomycin intermediate S. aureus (hVISA) and vancomycin intermediate S. aureus (VISA) to vancomycin by standard disk diffusion, microbroth dilution, a one-point population assay, and a population analysis profile. Sixty-eight MRSA isolates from patients admitted to Sanprasitthiprasong Hospital between November 2010 and November 2011 were tested. Standard disk diffusion showed that all the MRSA isolates were susceptible to vancomycin. Vancomycin MICs for all isolates were 1-2 microg/mL. Only two MRSA isolates (2.9%) were able to grow on brain heart infusion agar supplemented with vancomycin 4 microg/mL and were confirmed by a population analysis as hVISA. This study showed the effect of vancomycin on MRSA and the need for early detection and controlled planning.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Vancomicina hydrochloride from Streptomyces orientalis, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
Vancomicina hydrochloride from Streptomyces orientalis, ≥85% (Vancomycin B)
Sigma-Aldrich
Vancomicina hydrochloride from Streptomyces orientalis, BioReagent, suitable for plant cell culture
Sigma-Aldrich
Vancomicina hydrochloride from Streptomyces orientalis, meets USP testing specifications
Millipore
Vancomycin supplement, suitable for microbiology
Vancomycin hydrochloride, European Pharmacopoeia (EP) Reference Standard